CHEK1 and head and neck cancer: Cell cycle and PI3K pathway dysregulation have been reported in various tumors, and several clinical trials are currently ongoing to evaluate the clinical efficacy of monotherapies targeting CHK1 or PI3K in head and neck cancer [19,25].